TY - JOUR
T1 - Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease
AU - Vergaro, Giuseppe
AU - Aimo, Alberto
AU - Januzzi, James L.
AU - Richards, A. Mark
AU - Lam, Carolyn S.P.
AU - Latini, Roberto
AU - Staszewsky, Lidia
AU - Anand, Inder S.
AU - Ueland, Thor
AU - Rocca, Hans Peter Brunner La
AU - Bayes-Genis, Antoni
AU - Lupón, Josep
AU - de Boer, Rudolf A.
AU - Yoshihisa, Akiomi
AU - Takeishi, Yasuchika
AU - Gustafsson, Ida
AU - Eggers, Kai M.
AU - Huber, Kurt
AU - Gamble, Greg D.
AU - Leong, Kui Toh Gerard
AU - Yeo, Poh Shuan Daniel
AU - Ong, Hean Yee
AU - Jaufeerally, Fazlur
AU - Ng, Tze P.
AU - Troughton, Richard
AU - Doughty, Robert N.
AU - Emdin, Michele
AU - Passino, Claudio
N1 - Publisher Copyright:
Copyright © 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - AIMS: Chronic obstructive pulmonary disease (COPD) is a frequent comorbidity in patients with heart failure (HF). We assessed the influence of COPD on circulating levels and prognostic value of three HF biomarkers: N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), and soluble suppression of tumorigenesis-2 (sST2).METHODS: Individual data from patients with chronic HF, known COPD status, NT-proBNP and hs-TnT values (n = 8088) were analysed. A subgroup (n = 3414) had also sST2 values.RESULTS: Patients had a median age of 66 years (interquartile interval 57-74), 77% were men and 82% had HF with reduced ejection fraction. NT-proBNP, hs-TnT and sST2 were 1207 ng/l (487-2725), 17 ng/l (9-31) and 30 ng/ml (22-44), respectively. Patients with COPD (n = 1249, 15%) had higher NT-proBNP (P = 0.042) and hs-TnT (P < 0.001), but not sST2 (P = 0.165). Over a median 2.0-year follow-up (1.5-2.5), 1717 patients (21%) died, and 1298 (16%) died from cardiovascular causes; 2255 patients (28%) were hospitalized for HF over 1.8 years (0.9-2.1). NT-proBNP, hs-TnT and sST2 predicted the three end points regardless of COPD status. The best cut-offs from receiver-operating characteristics analysis were higher in patients with COPD than in those without. Patients with all three biomarkers higher than or equal to end-point- and COPD-status-specific cut-offs were also those with the worst prognosis.CONCLUSIONS: Among patients with HF, those with COPD have higher NT-proBNP and hs-TnT, but not sST2. All these biomarkers yield prognostic significance regardless of the COPD status.
AB - AIMS: Chronic obstructive pulmonary disease (COPD) is a frequent comorbidity in patients with heart failure (HF). We assessed the influence of COPD on circulating levels and prognostic value of three HF biomarkers: N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), and soluble suppression of tumorigenesis-2 (sST2).METHODS: Individual data from patients with chronic HF, known COPD status, NT-proBNP and hs-TnT values (n = 8088) were analysed. A subgroup (n = 3414) had also sST2 values.RESULTS: Patients had a median age of 66 years (interquartile interval 57-74), 77% were men and 82% had HF with reduced ejection fraction. NT-proBNP, hs-TnT and sST2 were 1207 ng/l (487-2725), 17 ng/l (9-31) and 30 ng/ml (22-44), respectively. Patients with COPD (n = 1249, 15%) had higher NT-proBNP (P = 0.042) and hs-TnT (P < 0.001), but not sST2 (P = 0.165). Over a median 2.0-year follow-up (1.5-2.5), 1717 patients (21%) died, and 1298 (16%) died from cardiovascular causes; 2255 patients (28%) were hospitalized for HF over 1.8 years (0.9-2.1). NT-proBNP, hs-TnT and sST2 predicted the three end points regardless of COPD status. The best cut-offs from receiver-operating characteristics analysis were higher in patients with COPD than in those without. Patients with all three biomarkers higher than or equal to end-point- and COPD-status-specific cut-offs were also those with the worst prognosis.CONCLUSIONS: Among patients with HF, those with COPD have higher NT-proBNP and hs-TnT, but not sST2. All these biomarkers yield prognostic significance regardless of the COPD status.
U2 - 10.2459/JCM.0000000000001281
DO - 10.2459/JCM.0000000000001281
M3 - Article
C2 - 34839321
AN - SCOPUS:85122546308
SN - 1558-2035
VL - 23
SP - 28
EP - 36
JO - Journal of cardiovascular medicine (Hagerstown, Md.)
JF - Journal of cardiovascular medicine (Hagerstown, Md.)
IS - 1
ER -